Neurodegenerative Disease News and Research

RSS

New protein atlas identifies distinct subtypes of neurodegenerative diseases

Neurodegenerative diseases form a tangled biological web with overlapping molecular signatures and symptoms. To decode this complexity, a multi-institute collaboration led by St. Jude Children's Research Hospital scientists developed the pan-neurodegeneration atlas (PanNDA).

23 Mar 2026

Oral semaglutide fails to slow early Alzheimer’s decline in two phase 3 trials

Two large phase 3 trials found that oral semaglutide 14 mg did not slow cognitive or functional decline over 104 weeks in people with early symptomatic, amyloid-positive Alzheimer’s disease. Semaglutide was generally consistent with its known safety profile and showed some biomarker changes, but these did not translate into clinical benefit.

22 Mar 2026

MIND diet may protect against structural brain deterioration

The combined Mediterranean and blood pressure lowering diet (MIND) may slow the structural changes related to brain aging, finds research published online in the Journal of Neurology Neurosurgery & Psychiatry.

17 Mar 2026

Study maps gene activity linked to neurotransmission in living brains

Researchers have identified a distinct and reproducible gene expression program associated with neurotransmission in the living human brain, offering unprecedented insight into the molecular mechanisms that support human cognition, emotion, and behavior.

16 Mar 2026

Lifelong tracking of fish reveals early behavioral signals of aging

Scientists tracking the entire life of the African turquoise killifish have discovered that behavior alone can predict whether an animal will live a long or short life.

12 Mar 2026

Scientists map epigenetic changes across aging brain cells

Neurodegenerative diseases affect more than 57 million people globally. The incidence of these diseases, from Alzheimer's to Parkinson's to ALS and beyond, is expected to double every 20 years.

11 Mar 2026

Single dose of CAR-astrocyte therapy halves amyloid levels in mice brains

The new generation of Alzheimer's disease drugs - the first proven to change the course of the disease - typically extend independent living for patients by 10 months.

6 Mar 2026

New research initiative aims to predict and prevent diseases before they start

What if doctors could tell you a disease was coming years before you felt a single symptom-and stop it in its tracks? That is the goal of a sweeping new research initiative launched by the Icahn School of Medicine at Mount Sinai in collaboration with the Uniformed Services University of the Health Sciences (USU) and the Henry M. Jackson Foundation for the Advancement of Military Medicine (HJF).

2 Mar 2026

Ultraprocessed foods are engineered like cigarettes

The parallels between ultraprocessed foods and tobacco raise concerns about addiction and health risks, urging policymakers to implement effective regulations.

2 Mar 2026

Antibiotics alter gut bacteria to aid brain healing

What if healing the brain after traumatic injury starts in the gut?

26 Feb 2026

Study finds brain changes related to worse memory in football players with repetitive head impacts

In former college and professional football players, a new study has found higher levels of inflammation were associated with worse brain structure, which in turn was related to worse memory.

25 Feb 2026

Major grant supports investigation into infectious triggers of Alzheimer’s and Parkinson’s

The Hebrew University of Jerusalem is proud to announce the establishment of the Sally Einstein Brain Research Program, made possible by a ₪1,000,000 (USD $300,930) grant from the Sim Einstein Research Foundation, Inc.

19 Feb 2026

Single blood test predicts onset of Alzheimer’s symptoms years ahead

Researchers at Washington University School of Medicine in St. Louis have developed a method to predict when someone is likely to develop symptoms of Alzheimer's disease using a single blood test.

19 Feb 2026

Can GLP-1 drugs slow neurodegeneration? New review finds promising signals but limited clinical proof

This review examines how GLP-1 receptor agonists may influence neurodegenerative disease biology through metabolic, inflammatory, mitochondrial, and proteostasis pathways. Evidence from mechanistic, preclinical, and early clinical studies suggests potential neuroprotective effects, but definitive disease-modifying benefit remains unproven.

17 Feb 2026

Scientists uncover nanoplastics in brain tissue and question their role in neurological disease

Emerging evidence suggests nanoplastics accumulate in human tissues including the brain and may contribute to neuroinflammation and neurodegenerative disease pathways. However, causality, exposure routes, and long-term health effects remain uncertain and require coordinated research.

17 Feb 2026

JAX-NYSCF collaborates with GSK to advance human cellular models of neurodegenerative disease

The Jackson Laboratory–New York Stem Cell Foundation Collaborative (JAX-NYSCF) today announced a five-year strategic research collaboration with GSK focused on advancing human cellular models of neurodegenerative disease, including Alzheimer's disease.

17 Feb 2026

Siemens Healthineers and Mayo Clinic expand partnership to fight neurodegenerative disease, cancer

Siemens Healthineers and Mayo Clinic are expanding their strategic collaboration to enhance patient care for neurodegenerative disease and the management of prostate cancer and metastatic liver tumors.

13 Feb 2026

Neuron lattice structure may guard against neurodegeneration

Brain cells are constantly swallowing material from the fluid that surrounds them - signaling molecules, nutrients, even pieces of their own surfaces - in a process known as endocytosis that is essential for learning, memory and basic neural upkeep.

11 Feb 2026

New roadmap integrates aging into Parkinson disease models

Even though aging is the largest risk factor for Parkinson's disease, the majority of research aimed at taming the able neurodegenerativeincur motor disease has largely left aging out of the mix.

11 Feb 2026

Alzheimer’s plaques decline after CAR-T immune cell treatment in preclinical study

Researchers engineered CD4+ chimeric antigen receptor T cells targeting fibrillar amyloid beta and tested them in a mouse Alzheimer model. The preclinical study showed reduced amyloid pathology and altered neuroimmune responses, supporting CAR-T immunotherapy as a potential future Alzheimer strategy.

11 Feb 2026